13 stories mentioning SHE:000739Updated just now
Every FINWIRES story that references SHE:000739, newest first.
The U.S. Food and Drug Administration approved Apeloa Pharmaceutical (SHE:000739) subsidiary Zhejiang Apeloa Jutai Pharmaceutical's abbreviated new drug application for its brivaracetam tablets, according to a Tuesday filing with the Shenzhen bourse.The drug is indicated for epilepsy-related partial-onset seizures, the filing said.
Apeloa Pharmaceutical (SHE:000739) unit Zhejiang Apeloa Tobang Pharmaceutical obtained marketing approval from China's drug regulator for the active pharmaceutical ingredient cefditoren pivoxil.The API is used to treat respiratory, urinary, biliary, skin and soft tissue infections, as well as obstetric, gynecological, ophthalmic and dental infections, according to a Thursday filing with the Shenzhen bourse.Shares of the pharmaceutical company slid 1% in recent trade.
Apeloa Pharmaceutical's (SHE:000739) unit, Zhejiang Apeloa Jiayuan Pharmaceutical, received approval from China's National Medical Products Administration for the marketing of an active pharmaceutical ingredient for Fulzerasib, according to a Thursday.The drug is used for the treatment of adults with advanced KRAS G12C-mutant non-small cell lung cancer.The Chinese pharmaceutical company's shares fell 2% during the afternoon trade.
Apeloa Pharmaceutical (SHE:000739) signed a strategic cooperation framework agreement with Jitai Technology Beijing to collaborate on contract development and manufacturing organization (CDMO) services and related projects.The five-year partnership positions Apeloa as the preferred CDMO provider for Jitai and its affiliates, while exploring new project companies and joint investments, according to a Tuesday filing with the Shenzhen bourse.
Apeloa Pharmaceutical's (SHE:000739) unit Zhejiang Apeloa Kangyu Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its levocarnitine oral solution, according to a Shenzhen bourse filing on Wednesday.The drug is used to treat primary systemic carnitine deficiency and secondary carnitine deficiency.The pharmaceutical company's shares jumped 5% during the afternoon trade.
Apeloa Pharmaceutical's (SHE:000739) subsidiary, Zhejiang Ante Yutai Biotechnology, entered into a cooperation agreement with Shanghai Wuxi Biologics and Shanghai Duoning Biotechnology, according to a Shenzhen bourse filing on Tuesday.Under the deal, Wuxi Biologics will provide research, development and manufacturing services to Ante Yutai.Duoning Biotech will also provide key consumables and supporting hardware to Ante Yutai for biologics research and development, and manufacturing.The pharmaceutical company's shares fell 3% during the afternoon trade.
Apeloa Pharmaceutical (SHE:000739) obtained a certificate of suitability from the European Union for the gabapentin active pharmaceutical ingredient, according to a Shenzhen bourse filing on Thursday.The drug is used for the treatment of postherpetic neuralgia in adults and epilepsy in children.The pharmaceutical company's shares fell nearly 2% during the afternoon trade.
Apeloa Pharmaceutical (SHE:000739) plans to establish a joint venture with three other investors, according to a Shenzhen bourse filing on Friday.The venture, Zhejiang Ante Yutai Biotechnology, will manufacture antibody and protein drugs, and other biopharmaceutical products and will have a registered capital of 10 million yuan.The company will own 34.6% of the venture.The pharmaceutical company's shares slumped 6% at the close.
Apeloa Pharmaceutical's (SHE:000739) unit, Zhejiang Apeloa Kangyu Pharmaceutical, received a certificate of suitability from the European Union for its amantadine hydrochloride, according to a Shenzhen bourse filing on Friday.The drug is used to treat symptoms caused by influenza A virus infection, as well as Parkinson's Disease.
The U.S. Food and Drug Administration approved Apeloa Pharmaceutical's (SHE:000739) metoprolol succinate extended-release tablets, according to a Friday disclosure to the Shenzhen bourse.The drug is indicated for hypertension and angina pectoris or chest pain, as well as symptomatic stable chronic heart failure with dysfunction in the left ventricle, among others.
China's drug regulator approved the cefpodoxime proxetil raw material produced by Apeloa Pharmaceutical (SHE:000739) Zhejiang subsidiary, according to a Saturday filing with the Shenzhen bourse.The ingredient is an antibiotic, suited for upper and lower respiratory tract infections, uncomplicated urinary tract infections, and other bacterial infections, the filing said.
Apeloa Pharmaceutical (SHE:000739) posted first-quarter attributable net profit of 249.0 million yuan, up 0.2% from 248.5 million yuan the previous year.Earnings per share rose to 0.2152 yuan from 0.2126 yuan, according to a Tuesday filing with the Shenzhen bourse.Operating revenue declined 10% year over year to 2.45 billion yuan from 2.73 billion yuan.Shares of the pharmaceutical company were up 4% in recent trade.
China's drug regulator approved Apeloa Pharmaceutical's (SHE:000739) registration for its fluvastatin sodium extended-release tablets, according to a Thursday filing with the Shenzhen bourse.Fluvastatin sodium is indicated for cholesterol lowering, the filing said.
